Point72 Asia Singapore Pte. Ltd. Makes New Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 247,866 shares of the biopharmaceutical company’s stock, valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.12% of Sangamo Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of SGMO. State Board of Administration of Florida Retirement System grew its holdings in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the period. Cubist Systematic Strategies LLC bought a new position in Sangamo Therapeutics in the second quarter worth $67,000. Acadian Asset Management LLC raised its holdings in Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Marshall Wace LLP lifted its position in Sangamo Therapeutics by 56.3% during the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 207,476 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sangamo Therapeutics during the 1st quarter valued at $331,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Sangamo Therapeutics has an average rating of “Hold” and a consensus price target of $2.67.

Sangamo Therapeutics Stock Down 1.5 %

Shares of SGMO opened at $0.78 on Friday. The company has a market capitalization of $162.07 million, a P/E ratio of -0.42 and a beta of 1.23. Sangamo Therapeutics, Inc. has a twelve month low of $0.29 and a twelve month high of $1.48. The firm has a 50 day moving average of $0.86 and a 200 day moving average of $0.64.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The business had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $11.40 million. On average, sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.